Researchers at the School of Medicine may have found a path toward improving the effectiveness of chemotherapy in people with breast or ovarian cancer caused by defects in one of the BRCA genes. The researchers identified a pair of genes that operate in parallel to BRCA and may increase susceptibility to chemotherapy drugs.
Ovarian cancer claims the lives of more than 14,000 women in the U.S. each year, ranking fifth among cancer deaths in women. A multidisciplinary team at Washington University has found an innovative way to use sound and light to diagnose ovarian tumors, which may lead to a promising new diagnostic imaging technique to improve current standard of care.
The National Institutes of Health has awarded a Washington University in St. Louis faculty member in the School of Engineering & Applied Science a total of $1.3 million to study new imaging techniques designed to better fight breast and ovarian cancers.
In a new analysis, researchers at the School of Medicine have shed light on the hereditary elements across 12 cancer types — showing a surprising inherited component to stomach cancer and providing some needed clarity on the consequences of certain types of mutations in well-known breast cancer susceptibility genes BRCA1 and BRCA2.
Washington University’s Bear Cub program is funding four innovative projects that have commercial potential. Pictured is William G. Hawkins, MD, who is developing a new treatment for pancreatic cancer.
A new study conservatively estimates that one in five women with ovarian cancer has inherited genetic mutations that increase the risk of the disease, according to research by the School of Medicine’s Li Ding, PhD, and her colleagues.